RFA-AR-25-014-Full-Announcement.html

The document is a Request for Application (RFA) for the Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials, issued by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) within the Department of Health and Human Services National Institutes of Health. This funding opportunity will utilize the UH3 activity code and is authorized through the 21st Century Cures Act, focusing on advancing regenerative medicine research using adult stem cells. While applications are not currently being solicited, the notice provides advance information to allow potential applicants time to develop collaborations and responsive projects.

The grant opportunity is associated with multiple federal grant programs, including Arthritis, Musculoskeletal and Skin Diseases Research (CFDA 93.846), Lung Diseases Research (CFDA 93.838), Cardiovascular Diseases Research (CFDA 93.837), and Translation and Implementation Science Research (CFDA 93.840). Investigators previously funded through the Regenerative Medicine Innovation Project are specifically encouraged to consider applying for this new Notice of Funding Opportunity (NOFO). The cooperative agreement funding instrument suggests collaborative research between the funding agency and selected researchers, with the ultimate goal of supporting innovative clinical trials in regenerative medicine.